MZMarco Mounir Zaki

Marco Mounir Zaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marco Mounir Zaki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • M. Abdelkawy

    Cairo University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Kasr El-Aini St, 11562 Cairo, Egypt

    2 shared publications
  • Nada S. Abdelwahab

    Beni-Suef University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Alshaheed Shehata Ahmed Hegazy St, 62514 Beni-Suef, Egypt

    2 shared publications
  • Adel Ahmed Ali

    Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

    1 shared publication
  • Eglal A. Abdelaleem

    Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

    1 shared publication
  • Loah R. Hemeda

    Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt

    1 shared publication
  • Manar A. Mohamed

    Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt

    1 shared publication

Latest Publications

  • Open Access

    FDA validated ecofriendly HPTLC method for quantification of Florfenicol and Meloxicam in bovine tissues with sustainability assessment

    by Marco M. Z. Sharkawi, Eglal A. Abdelaleem, Manar A. Mohamed, Mohamed Ahmed Elsayed

    Meloxicam and Florfenicol, two pharmacologically distinct agents with anti-inflammatory and antibacterial properties, respectively, have attracted considerable interest in veterinary medicine due to their therapeutic efficacy and safety profiles, particularly in cattle and poultry. In this study, a cost-effective and straightforward thin-layer chromatography (HPTLC) densitometric method was developed for the simultaneous Quantification of these drugs in both pharmaceutical formulations and spiked bovine muscle samples, with the aim of monitoring tissue residues. The chromatographic separation was achieved using a mobile phase consisting of glacial acetic acid, methanol, triethylamine, and ethyl acetate (0.05: 1.00: 0.10: 9.00, by volume). Densitometric detection was performed at 230 nm, with Esomeprazole (ESO) employed as an internal standard to compensate for potential wavelength fluctuations. Method validation was conducted in accordance with ICH guidelines, demonstrating Linearity within the ranges of 0.03–3.00 µg/band for meloxicam and 0.50–9.00 µg/band for Florfenicol. This method offers a reliable analytical tool for regulatory and surveillance purposes, contributing to public health protection and food safety by enabling the detection of veterinary drug residues in edible tissues. The environmental impact of the method was evaluated using five greenness assessment tools, including greenness, whiteness, and blueness metrics, confirming its eco-friendly nature.


  • Open Access

    Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study

    by Marco M. Z. Sharkawi, Noha H. Amin, Norhan R. Mohamed, Shimaa S. Zaki, Loah R. Hemeda

    Multiple myeloma (MM) is a blood cancer that, unfortunately, has a high morbidity and mortality rate. The VMP regimen, which includes bortezomib (BOR), melphalan (MEL), and prednisolone (PRD), is a safe and effective salvage regimen for refractory or relapsed MM. Up to now, there is no established analytical method to determine the VMP regimen, nor has any study investigated the kinetic interactions among its components, thereby highlighting the need for further clinical investigation. In light of this, an environmentally friendly, fast, sensitive, and precise LC-MS/MS method was established to determine bortezomib, melphalan, prednisolone, and sildenafil (an internal standard) simultaneously as part of the in vivo pharmacokinetics research carried out on rats. The established LC-MS/MS method was applied using a mobile phase composed of a mixture of methanol: 0.1% aqueous solution of formic acid and a ZORBAX Eclipse Plus C18 column (4.6 mm × 150 mm, 5 μm) as a stationary phase. The cited drugs were ionized through positive ionization and detected using multi-reaction monitoring (MRM) mode with the following precursor→product transitions: m/z 367.3→226.3 for BOR, m/z 305.0→168.2 for MEL, m/z 545.0→147.5 for PRD, and m/z 475.3→283.4 for SIL. Following FDA guidelines, the developed method was validated and showed acceptable ranges. Subsequently, it was employed in an in vivo investigation using rats, where the quantitative assessment of each drug was performed following both single and combined treatment. This allowed for the investigation of potential drug-drug interactions and the calculation of all pharmacokinetic parameters to monitor the therapeutic effects of those medications. To ensure the safety and environmental friendliness of the developed method, four assessment tools were applied: the assessment of green profile (AGP), blue applicability grade index (BAGI), analytical greenness metric for sample preparation (AGREEprep), and green analytical procedure index (GAPI).


  • Open Access

    Simultaneous determination of bisoprolol fumarate and rosuvastatin calcium in a new combined formulation by validated RP-HPLC

    by Marco Mounir Zaki, Nada Sayed Abdelwahab, Adel Ahmed Ali, Souty Mounie Zaki Sharkawi

    A simple, specific, and precise RP-HPLC method was developed and validated for simultaneous determination of Bisoprolol fumarate (BIS) and Rosuvastatin calcium (ROS) in new formulated tablets. The developed RP-HPLC method depended on chromatographic separation using C18 column (150×4.6 mm, 0.5 μm) with mobile phase consisted of acetonitrile and 0.05 aqueous solution of orthophosphoric acid at the ratio of 65:35 % (v:v) with a flow rate of 1 mL/min and UV detection was carried out at 230 nm. Factors affecting the developed methods were studied and optimized and the retention times for BIS and ROS were found to be 2.758 and 4.974 min, respectively. Linearity of the proposed method was observed over a concentration range 0.2-50 μg/mL for each of BIS (r = 0.9999) and ROS (r = 0.9998). The proposed method was successfully applied for the determination of the studied drugs in their bulk powder, laboratory prepared mixtures and in the formulated tablets. The developed method is the first chromatographic method for determination of those drugs and showed no significant difference when compared with the reported methods.


  • Simultaneous Determination of Thalidomide and Dexamethasone in Rat Plasma by Validated HPLC and HPTLC With Pharmacokinetic Study

    by Nada S Abdelwahab, Nouruddin W Ali, Marco M Zaki, Souty M Z Sharkawi, Mohamed M Abdelkawy

    Two validated chromatographic methods have been developed for the simultaneous determination of thalidomide (THD) and dexamethasone (DEX) in rat plasma using paracetamol (PAR) as an internal standard (IS). Chromatographic analysis was achieved firstly by HPLC method on C18 column (150 × 4.6 mm2 i.d., 5 μm) and a mobile phase composed of ethanol:water (containing 0.1% acetic acid) (70:30, v/v) at the flow rate of 0.6 mL min−1. The second method was HPTLC method which depended on using a developing system of methylene chloride:acetone:ethyl acetate (7:4:1, by volume). In both methods, PAR was used as an IS. The developed methods have been validated as per FDA guidelines. All parameters were tested using quality control samples (LQC, MQC and HQC). All the obtained parameters were within the acceptance criteria. In the same way, the two methods were successfully used to study the pharmacokinetic parameters of both THD and DEX after their intra-peritoneal administration. Moreover, results obtained after administration of each drug alone were compared to those obtained after their administration together. The drugs showed drug–drug interactions when administered in combination, meaning that monitoring of such combination is very important.


  • Quantitative Determination of Synthesized Genotoxic Impurities in Nifuroxazide Capsules by Validated Chromatographic Methods

    by Nada S. Abdelwahab, Nouruddin W. Ali, Marco M. Zaki, M. Abdelkawy, Mohammed T. El-Saadi

    Two accurate, selective, and precise chromatographic methods, namely TLC-densitometric and reversed-phase (RP)-HPLC, were developed and validated for the simultaneous determination of nifuroxazide (NIF) and its four synthesized impurities, which are also reported to be its related substances in the range of 10–100 μg/band and 10–100 μg/mL for NIF in the TLC and RP-HPLC methods, respectively. The developed TLC-densitometric method depended on the separation and quantitation of the studied components on silica gel 60 F254 TLC plates. Ethyl acetate–acetone–methanol–ammonia (85 + 25 + 5 + 0.5, v/v/v/v) was used as the developing system, and the separated bands were UV-scanned at 230 nm. On the other hand, the developed RP-HPLC method depended on chromatographic separation using a C8 column at 25°C and an aqueous solution of 0.1% sodium lauryl sulfate–acetonitrile as the mobile phase delivered according to the gradient elution program. Factors affecting the developed methods were studied and optimized. Also, method validation was carried out according to International Conference on Harmonization guidelines. The proposed methods were successfully applied for the determination of the studied drug in its bulk powder and in its pharmaceutical formulation. The developed methods showed no significant difference when compared with the reported RP-HPLC one. Their advantage is being the first stability-indicating methods for NIF and its genotoxic impurities.


  • Open Access

    Validated Chromatographic Methods for Simultaneous Determination of Tolfenamic Acid and Its Major Impurities

    by Nada S. Abdelwahab, Nouruddin W. Ali, Marco M. Zaki, M. Abdelkawy

    Two accurate, selective and precise chromatographic methods, namely thin-layer chromatography (TLC)-densitometric method and reversed phase high-performance liquid chromatography (RP-HPLC) method, were developed and validated for the simultaneous determination of tolfenamic acid (TOL) and its two major impurities, 2-chlorobenzoic acid (CBA) and 3-chloro-2-methylaniline (CMA), which are also reported to be its related substances. The developed TLC-densitometric method depended on separation and quantitation of the studied drugs on silica gel 60F254 TLC plates. Hexane:chloroform:acetone:acetic acid (75:25:20:0.1, v/v/v/v) was used as a developing system and the separated bands were UV-scanned at 240 nm. Linear relationships were obtained in the range of 10–100 µg band−1 for the drug and in the range of 0.1–1 µg band−1 for the studied impurities. The developed RP-HPLC depended on chromatographic separation of the studied drugs on a C18 column using 0.05 M KH2PO4 buffer (pH 3):acetonitrile (45:55, v/v) as a mobile phase delivered at constant flow rate of 1 mL min−1 with UV detection at 230 nm. Calibration curves for TOL and the two impurities were constructed over the concentration ranges of 10–100 µg mL−1 for TOL and 0.01–0.1 µg mL−1 for both CBA and CMA. Factors affecting the developed methods have been studied and optimized. Further, methods validation has been carried out according to International Conference on Harmonization guidelines. The proposed methods were successfully applied for determination of the studied drug in its bulk powder and in pharmaceutical formulation. The methods showed no significant difference when compared with the reported RP-HPLC one. The developed methods have advantages of being more sensitive and specific than the published methods.